Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma



Status:Completed
Conditions:Prostate Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:6/27/2018
Start Date:June 2006
End Date:September 2016

Use our guide to learn which trials are right for you!

CSP #553 - Adjuvant Therapy in Prostate Carcinoma Treatment

VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early
adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for
patients who are potentially cured by radical prostatectomy but who are at high risk for
relapse. The standard of care is surveillance, with the addition of androgen deprivation at
the time of biochemical relapse. This study will assess the effect of adding early
chemotherapy to the standard of care on progression free survival in Veterans at high risk
for progression after prostatectomy.

VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early
adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for
patients who are potentially cured by radical prostatectomy but who are at high risk for
relapse. The standard of care is surveillance, with the addition of androgen deprivation at
the time of biochemical relapse. This study will assess the effect of adding early
chemotherapy to the standard of care on progression free survival in Veterans at high risk
for progression after prostatectomy.

The ability of radical prostatectomy to cure prostate cancer and to therefore prevent the
morbidity and mortality associated with progression to metastatic disease depends on
effectively treating both local and potential systemic disease. In the United States alone,
over 80,000 men per year are treated with prostatectomy to cure their disease. Because 20% of
these men will be found to have locally advanced or high-grade disease, they will be at risk
for relapse and morbidity from their prostate cancer. Although androgen deprivation,
radiation therapy, and chemotherapy have been considered potentially effective adjuvant
modalities for localized prostate cancer, there are no randomized studies that support the
utility of any of these treatments as a standard of care. Ultimately, it is androgen
independent prostate cancer, which causes morbidity for these patients. Docetaxel based
chemotherapy has been shown to prolong survival and induce responses in up to 80% of patients
with androgen independent disease, generating enthusiasm for the use of chemotherapy early in
the treatment of prostate cancer. This study is designed to test the value of adjuvant
chemotherapy in improving progression free survival, which is critical in preventing
morbidity and mortality from relapse in patients with clinically localized, but high risk,
prostate cancer.

After patients are stratified for PSA, Gleason score, tumor stage, the presence of positive
margins, and the planned use of adjuvant radiation therapy, this study will randomized 300
patients from 30 VA sites, after prostatectomy, to the standard of care or to docetaxel and
prednisone administered every 3 weeks for 18 weeks. Patients would then be observed with PSA
for a minimum of one and a maximum of five years. The study is designed with 90% power to
detect a reduction in the 5-year progression rate from 60% to 45% (15% absolute difference,
25% relative difference).

At the end of the study period (October 31, 2012), the patients in the study will continue to
be passively followed for three more years. The follow-up study involved centralized remote
access of the participants' medical records to obtain information on PSA levels and study
endpoints.

Prostate cancer is the leading cause of malignancy for Veterans, and the second leading cause
of death. Patients with high risk, localized disease account for 70% of all cancer deaths in
patients treated for cure with radical prostatectomy. Effective adjuvant therapy is critical
to reducing suffering and death from prostate cancer. The VA Cooperative Studies Program is
uniquely placed to address this question. The VA has a longstanding history of important
studies in prostate cancer, which have significantly changed the way urologic oncologists
treat patients with this disease. The incidence of prostate cancer in our older, male
population is substantial, the number of Veterans treated with prostatectomy continues to
rise, and the incidence of high risk prostate cancer in Veterans is greater than that
typically found in the community. For all of these reasons, carrying out this study within
the VA through the VA Cooperative Studies Program is the optimal way to determine whether
adjuvant chemotherapy will benefit men with high risk prostate cancer.

Inclusion Criteria:

- A histologic diagnosis of cT1-T2 primary adenocarcinoma of the prostate prior to
prostatectomy, with lymph node dissection at time of radical prostatectomy

- One or more of the following poor prognostic features:

- tumor extension to seminal vesicle (pT3b) or bladder neck (T4)

- established extracapsular extension (pT3a) and Gleason Score >= 7

- organ confined (pT2) with positive surgical margin and Gleason 8-10

- preoperative PSA > 20

- SWOG performance status 0-1

- PSA nadir of <= 0.1 ng/ml up to 30 days prior to randomization. Patients must be
randomized within 120 days after prostatectomy.

- Laboratory values (no more than 30 days before randomization) must be as follows:

- Absolute granulocyte count: >= 1,500/mm3

- Platelets: >= 100,000/mm3

- Hemoglobin: >= 10 g/dL

- Serum Creatinine: <= 1.5 x ULN

- AST: <= 1.5 x ULN

- ALT: <= 1.5 x ULN

- Serum Calcium: <= ULN

- Total Bilirubin: <=ULN

- Plasma Phosphorus Level: <= 6 mg/dl

- Patients with preoperative PSA > 20 ng/mL must have a negative bone scan within 120
days of randomization

- A valid, signed, and witnessed informed consent by the patient

Exclusion Criteria:

- Small cell histology

- N1 disease or M1 disease

- Clinical T3 disease prior to prostatectomy

- Any other investigational therapy

- An active serious infection or other serious underlying medical condition that would
otherwise impair their ability to receive protocol treatment

- A history of cancer related hypercalcemia

- Uncontrolled heart failure

- Prior malignancy other than curatively treated squamous cell or basal cell carcinoma
of the skin. If another malignancy has been treated and there is no evidence of
relapse > 5 years from the time of treatment, patients are eligible

- Androgen deprivation, chemotherapy, or radiation therapy to treat prostate carcinoma

- Current peripheral neuropathy of any etiology that is greater than Grade I
We found this trial at
34
sites
Augusta, Georgia 30904
?
mi
from
Augusta, GA
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Miami, Florida 33125
?
mi
from
Miami, FL
Click here to add this to my saved trials
Albuquerque, New Mexico 87108
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Ann Arbor, Michigan 48113
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Birmingham, Alabama 35233
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Charleston, South Carolina 29401
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Chicago, Illinois 60612
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Kansas City, Missouri 64128
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lexington, Kentucky 40502
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Long Beach, California 90822
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
?
mi
from
Madison, WI
Click here to add this to my saved trials
Memphis, Tennessee 38104
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Minneapolis, Minnesota 55417
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15240
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Portland, Oregon 97201
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Diego, California 92161
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Francisco, California 94121
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
San Juan, 00921
?
mi
from
San Juan,
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Shreveport, Louisiana 71101
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
West Haven, Connecticut 06516
?
mi
from
West Haven, CT
Click here to add this to my saved trials
West Los Angeles, California 90073
?
mi
from
West Los Angeles, CA
Click here to add this to my saved trials